Siemens, Krelo in Graves' disease test pact:
This article was originally published in Clinica
Siemens Medical Solutions Diagnostics has inked a deal with German IVD company KreLo GmbH Medical Diagnostics to develop an assay used in the differential diagnosis of Graves' disease, a condition that affects around 32 million people worldwide. The assay, designed to detect stimulating TSH receptor autoantibodies (TRAb), will be the first test of its kind to feature Krelo's proprietary TRAb biomarkers. Graves' disease is one of the most common forms of hyperthyroidism. It is characterised by the presence of TSH receptor autoantibodies, which mimic the activity of TSH, resulting in the elevated production of thyroid hormone. If left untreated, Graves' disease can lead to miscarriage, birth defects, thyroid eye disease and can be life-threatening.